These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Neuroendocrine responses to intravenous infusion of physostigmine in patients with Alzheimer disease. Asthana S; Raffaele KC; Greig NH; Schapiro MB; Blackman MR; Soncrant TT Alzheimer Dis Assoc Disord; 1999; 13(2):102-8. PubMed ID: 10372954 [TBL] [Abstract][Full Text] [Related]
4. Improved verbal learning after outpatient oral physostigmine therapy in patients with dementia of the Alzheimer type. Sevush S; Guterman A; Villalon AV J Clin Psychiatry; 1991 Jul; 52(7):300-3. PubMed ID: 2071560 [TBL] [Abstract][Full Text] [Related]
5. Oral physostigmine and lecithin improve memory in Alzheimer disease. Thal LJ; Fuld PA; Masur DM; Sharpless NS Ann Neurol; 1983 May; 13(5):491-6. PubMed ID: 6347034 [TBL] [Abstract][Full Text] [Related]
6. Effects of physostigmine and lecithin on memory in Alzheimer disease. Peters BH; Levin HS Ann Neurol; 1979 Sep; 6(3):219-21. PubMed ID: 534419 [TBL] [Abstract][Full Text] [Related]
7. No effect from double-blind trial of physostigmine and lecithin in Alzheimer disease. Wettstein A Ann Neurol; 1983 Feb; 13(2):210-2. PubMed ID: 6830183 [TBL] [Abstract][Full Text] [Related]
8. Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease. Eptastigmine Study Group. Canal N; Imbimbo BP Clin Pharmacol Ther; 1996 Aug; 60(2):218-28. PubMed ID: 8823240 [TBL] [Abstract][Full Text] [Related]
9. Effects of oral physostigmine in Alzheimer's disease. Stern Y; Sano M; Mayeux R Ann Neurol; 1987 Sep; 22(3):306-10. PubMed ID: 3674795 [TBL] [Abstract][Full Text] [Related]